Healthy Skepticism Library item: 10151
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
Glaxo cervical cancer shot approved in Australia
Reuters 2007 May 21
http://investing.reuters.co.uk/news/articleinvesting.aspx?type=allBreakingNews&storyID=2007-05-21T074146Z_01_L21497788_RTRIDST_0_GLAXO-CERVARIX-UPDATE-1.XML
Full text:
LONDON, May 21 (Reuters) – GlaxoSmithKline Plc said on Monday that Australia had become the first major country to approve its new cervical cancer vaccine, Cervarix.
Europe’s biggest drugmaker said Cervarix, one of its biggest new drug hopes, had been approved for use in women aged 10 to 45 years old.
Glaxo expects to launch Cervarix in Europe later this year but it may not get to market in the United States before 2008.
Cervarix will compete with Merck & Co. Inc.‘s Gardasil, which is already widely available worldwide. Despite that lag Glaxo is confident Cervarix can still carve out a substantial business, especially in treating older women.
Both vaccines protect against cancer-causing strains of the sexually transmitted human papillomavirus (HPV). They are expected to create a multibillion-dollar market, although most analysts think Merck’s first-mover advantage will win it the lion’s share.
